Abstract: A method is provided for isolating protease resistant antimicrobial peptides (AMPs) from a peptide display library. A plurality of nucleic acid constructs that encode displayed peptides are expressed, resulting in the formation of a plurality of peptide-nucleic acid complexes, each complex comprising at least one displayed peptide associated with the corresponding nucleic acid construct encoding the displayed peptide. The complexes are exposed to at least one protease, to allow the proteolysis of protease-sensitive peptides, such that resistant peptides remain. The peptide-nucleic acid complexes are further exposed to a membrane composition to allow association of complexes that contain membrane-associating peptides. Complexes that remain unassociated with the membrane are removed; and membrane-associated complexes are recovered. The AMPs so characterised may be resistant to one or more protease enzymes and exhibit antimicrobial activity against one or more microbe.

Abstract: The present invention relates to a biocidal fusion peptide comprising: a) a peptide LL-37 or an active fragment or active derivative thereof; b) and a further heterologous bioactive peptide or an active fragment thereof, wherein part or all of the amino acid sequence of the fusion peptide is predicted to form an alpha-helix structure for disruption of a pathogen membrane, compositions such as pharmaceutical compositions comprising the same, methods of preparing the peptide and use of the peptides in treatment, in particular for the treatment of bacterial infection and/or fungal infection and/or viral infection.

Abstract: The present invention relates to a biocidal fusion peptide of SEQ ID NO: 1 or a sequence with at least 90% identity thereto, compositions such as pharmaceutical compositions comprising the same, methods of preparing the peptide, and use of the peptide in treatment, in particular for the treatment of bacterial infection and/or fungal infection and/or viral infection.